Evidence map›Paper›PMID 41013029›Full record

ReviewSensors (Basel, Switzerland)2025

AI-Enabled Microfluidics for Respiratory Pathogen Detection.

Daoguangyao Zhang, Xuefei Lv, Hao Jiang, Yunlong Fan, Kexin Liu, Hao Wang, Yulin Deng

Abstract readReview
In one paragraph

Review in Sensors (Basel, Switzerland), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Review
  2. Review
  3. Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Daoguangyao ZhangSchool of Medical Technology, Beijing Institute of Technology, Beijing 100081, China.
Xuefei LvSchool of Medical Technology, Beijing Institute of Technology, Beijing 100081, China.
Hao JiangSchool of Medical Technology, Beijing Institute of Technology, Beijing 100081, China.
Yunlong FanCollege of Pharmaceutical Sciences, Zhejiang University, Hangzhou 310058, China.
Kexin LiuSchool of Medical Technology, Beijing Institute of Technology, Beijing 100081, China.
Hao WangSchool of Medical Technology, Beijing Institute of Technology, Beijing 100081, China.
Yulin DengSchool of Medical Technology, Beijing Institute of Technology, Beijing 100081, China.ORCID 0000-0002-0720-4052

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Respiratory infectious diseases, such as COVID-19, influenza, and tuberculosis, continue to impose a significant global health burden, underscoring the urgent demand for rapid, sensitive, and cost-effective diagnostic technologies. Integrated microfluidic platforms offer compelling advantages through miniaturization, automation, and high-throughput processing, enabling "sample-in, answer-out" workflows suitable for point-of-care applications. However, their clinical deployment faces challenges, including the complexity of sample matrices, low-abundance target detection, and the need for reliable multiplexing. The convergence of artificial intelligence (AI) with microfluidic systems has emerged as a transformative paradigm, addressing these limitations by optimizing chip design, automating sample pre-processing, enhancing signal interpretation, and enabling real-time feedback control. This critical review surveys AI-enabled strategies across each functional layer of respiratory pathogen diagnostics: from chip architecture and fluidic control to amplification analysis, signal prediction, and smartphone/IoT-linked decision support. We highlight key areas where AI offers measurable benefits over conventional methods. To transition from research prototypes to clinical tools, future systems must become more adaptive, data-efficient, and clinically insightful. Advances such as sensor-integrated chips, privacy-preserving machine learning, and multimodal data fusion will be essential to ensure robust performance and meaningful outputs across diverse scenarios. This review outlines recent progress, current limitations, and future directions. The rapid development of AI and microfluidics presents exciting opportunities for next-generation pathogen diagnostics, and we hope this work contributes to the advancement of intelligent, point-of-care testing (POCT) solutions.

Indexed as

Artificial IntelligenceMicrofluidic Analytical TechniquesMicrofluidicsRespiratory Tract InfectionsBiosensing TechniquesCOVID-19HumansLab-On-A-Chip DevicesMachine LearningPoint-of-Care SystemsSARS-CoV-2artificial intelligenceintegrated microfluidicsintelligent diagnosticsPOCTrespiratory pathogens

Identifiers

PMID41013029
PMCPMC12473228

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.